Pharmaceuticals

Krystexxa Market 2026 growing with gout treatment demand

March 29, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Krystexxa Market At The End Of The 2026–2030 Forecast Period?

Historical growth was propelled by the constraints of standard gout treatments, the rising occurrence of chronic gout, the proven clinical efficacy of pegloticase, an increase in co-existing medical conditions, and the expansion of specialized rheumatology practices.

The anticipated expansion over the forecast period is primarily driven by an increasing population of patients suffering from refractory gout, a rise in referrals to specialized clinics, the broadening of infusion services, favorable reimbursement policies for biologic treatments, and the ongoing unmet medical need in severe gout.

Significant trends anticipated within the forecast period comprise the expansion of biologic therapies for refractory gout, a heightened focus on uric acid-lowering enzyme treatments, the specialized management of patients with chronic gout, the wider availability of infusion-based rheumatology care, and an increasing application in severe and treatment-resistant scenarios.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20134&type=smp

Which Market Drivers Are Supporting The Expansion Of The Krystexxa Market?

An upward trend in the occurrence of gout disease is anticipated to drive the expansion of the Krystexxa market moving ahead. Gout is an inflammatory arthritis characterized by the accumulation of uric acid crystals within joints, resulting in inflammation, discomfort, and swelling. This rise in gout prevalence stems from various factors, including unhealthy eating patterns, excess weight, advancing age, specific drugs, genetic predisposition, long-term kidney issues, inactivity, and co-occurring conditions such as hypertension and diabetes. Krystexxa (pegloticase) assists individuals with gout by reducing blood uric acid concentrations, particularly addressing chronic cases unresponsive to standard therapies, consequently lessening the occurrence and intensity of gout attacks and alleviating the painful signs linked with this ailment. As an example, a report from June 2024 by Rheumatology and Therapy, an international peer-reviewed medical journal based in the US, indicated that the presence of co-occurring gout and chronic kidney disease in the United States was forecast to rise from 7.9 million in 2023 to 8.6 million in 2027, subsequently to 9.2 million in 2031, and reaching 9.6 million in 2035, which signifies a 29% increase between 2023 and 2035. Consequently, the growing occurrence of gout is propelling the Krystexxa market.

What Segment Types Make Up The Krystexxa Market?

The krystexxa market covered in this report is segmented –

1) By Formulation: Injectable Formulation (Lyophilized Powder), Ready-To-Use Solutions

2) By Indication: Treatment Of Chronic Gout, Management Of Hyperuricemia In Gout Patients, Treatment Of Refractory Gout

3) By Patient Demographics: Adult Patients, Elderly Patients, Patients With Comorbid Conditions

4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies

5) By End User: Hospitals, Specialty Clinics, Rheumatology Practices, Home Healthcare Providers

Which Market Trends Are Creating New Opportunities In The Krystexxa Market?

A significant trend within the krystexxa market centers on advancing immunomodulatory strategies, such as the rheumatology research dissemination initiative, to boost the visibility of clinical evidence, aid in informed therapeutic decision-making, and deepen stakeholder understanding of emerging progress in managing inflammatory and autoimmune diseases. The rheumatology research dissemination initiative itself represents a structured scientific communication effort designed to present, share, and promote new clinical findings, therapeutic data, and investigational insights within the field of rheumatology. For instance, in June 2024, Amgen Inc., a US-based biotechnology company, showcased innovative rheumatology research at the European Alliance of Associations for Rheumatology (EULAR) 2024 Congress, highlighting novel clinical data pertaining to Krystexxa (pegloticase). This research offered expanded evidence on patterns of treatment response, patient-reported outcomes, and immunologic behavior when utilizing advanced therapeutic combinations. Krystexxa, a PEGylated uricase enzyme therapy, continues to exhibit unique clinical benefits for adults with uncontrolled chronic gout by leveraging precision immune modulation to enhance efficacy and manage anti-drug antibody formation. These recent insights presented by Amgen further reinforce Krystexxa’s standing as a leading biologic option for patients with severe gout who have not adequately responded to conventional therapies.

Who Are The Key Players Driving Competition In The Krystexxa Market?

Major companies operating in the krystexxa market are Amgen Inc.

Read the full krystexxa market report here:

https://www.thebusinessresearchcompany.com/report/krystexxa-global-market-report

How Is The Krystexxa Market Distributed Across Key Geographic Regions?

North America was the largest region in the krystexxa market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the krystexxa market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Krystexxa Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20134&type=smp

Browse Through More Reports Similar to the Global Krystexxa Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Inductor Market Market Report 2026

https://www.thebusinessresearchcompany.com/report/inductor-market-global-market-report

Trade Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-finance-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795